Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

The U.S.-based NEW DAY clinical trial enrolled 306 patients with diabetic macular edema who received a single Iluvien ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study ...

ILUVIEN revenues should pick up by the end of the year. DME is a chronic disease and there is a desperate need for a sustained release treatment and ILUVIEN fills that need very well.

“From a creative standpoint, the campaign was focused on bringing light to having something like Iluvien and how that would be beneficial to their lifestyle,” Hoffman said. “If you are dealing with ...

ILUVIEN is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did ...

This note focuses on the implications of the complete response letter (( CRL)) received by Alimera ( ALIM) for Iluvien. This product was developed by pSivida ( PSDV) but was partnered with Alimera ...

Recently, the FDA approved a new option - Iluvien. It is a 3.5 millimeter rod of steroids which is implanted into the eye, and it lasts 3 years.

ILUVIEN is approved in the U.S., Canada, Australia, Kuwait, Lebanon and the U.A.E. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of ...

Iluvien is expected to be resubmitted in the first quarter. Once approved, pSivida will get a $25 million milestone payment from Alimera along with 20% of net profits on U.S. sales of Iluvien for DME.